Haleon plc American Depositary Shares (Each representing two Ordinary Shares)
HLN · NYSE
HLN · NYSE
Haleon is a consumer-health company selling over-the-counter medicines and everyday health products under brands including Advil, Sensodyne, Centrum, Panadol and Voltaren. It makes money by selling branded consumer products through retail, pharmacy and other distribution channels, serving consumers and healthcare-related shoppers rather than relying on a single prescription-drug franchise. The supplied evidence does not provide segment contributions, revenue, geographic mix or employee figures. It does establish a broad international footprint, with recent growth supported by North America and emerging markets, and a portfolio spanning pain relief, oral health and vitamins.
Haleon fell 4.77% over the period, from $10.27 to $9.78. The stock was little changed initially, edging from $10.27 to $10.28, before declining to $10.11 on July 30 and $9.87 on July 31; it then extended the slide to $9.80 and $9.78 on August 3-4. The supplied evidence does not identify a dated company-specific catalyst for the selling. Haleon's reported second-quarter organic sales growth accelerated to 3.1% from 2.2% in the first quarter, helped by North American execution and emerging-market growth, but that positive operating update did not prevent the decline. No broader market or sector explanation is supplied, so the week's move remains unexplained by the available evidence.
